Overall, testing for moderate- or high-penetrance BRCA1/2, RAD51C, RAD51D, BRIP1, and mismatch repair genes for the patients with epithelial ovarian cancer is recommended. This evidence concerns the gene RAD51C and ovarian carcinoma.